[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Other Articles
June 16, 1962

The Use of Aminopyrine to Control Fever in Hodgkin's Disease

Author Affiliations

Brooklyn. N.Y.

JAMA. 1962;180(11):970-972. doi:10.1001/jama.1962.03050240066018
Abstract

SINCE HODGKIN'S DISEASE was first described in 1832, x-rays, alkylating agents, antimetabolites, and steroids have become available as therapeutic agents. Nevertheless, therapy of the disease continues to remain a problem, and management, particularly in the later stages after dissemination has occurred, is still unsatisfactory. Fever is one of the more bothersome symptoms with which the physician has to deal. A simple method of treating this fever is used so little that it is worth reporting in some detail.

The fever of Hodgkin's disease may be continuous, but more usually is relapsing (Pel-Ebstein fever). Its incidence is variously reported to be from 30% to 50%. When fever does occur, it is usually a cause of disability by virtue of the malaise, weakness, sweating, anorexia, and headache, which are the direct consequences of elevated body temperatures. If the disease is left to run an uninhibited febrile course, it is usual for the

References
1.
Hodgkin, T., and Lee, R.:  On Some Morbid Appearance of Absorbent Glands and Spleen ,  Med Chir Tr 17:68, 1832.
2.
Ebstein, W.:  Daschronische Rüsksfallsfieber; eine neue Infektionskrankheit ,  Klin Wschr 24:565, 837, 1887.
3.
Pel, P. K.:  zur Symptomatologie der sogennanten Pseudo-Leukämie ,  Klin Schnschr 22:3, 1885.
4.
Hoster, H. A., and Dratman, M. B.:  Hodgkin's Disease; 1832-1942 ,  Cancer Res 8:1, 1948.
5.
Cardon, L., et al.:  Value of Aminopyrine ,  Ann Intern Med 48:616, 1958.Crossref
6.
Kracke, R. R., and Parker, E. P.:  Relationship of Drug Therapy to Agranulocytosis ,  JAMA 105:960, 1935.Crossref
7.
Schultz, W.:  Uber einartige Halserkrankungen ,  Deutsch Med Wschr 48:1495, 1922.
8.
Kracke, R. R.:  Recurrent Agranulocytosis ,  Amer J Clin Path 1:385, 1931.
9.
Driscombe, G.:  Agranulocytosis Caused by Aminopyrine: Avoidable Cause of Death ,  Brit Med J 1:1270, 1952.Crossref
10.
Reznikoff, P.:  Relation of Aminopyrine Barbituric Acid Derivatives to Granulocytopenia, Special Report of Council on Pharmacy and Chemistry ,  JAMA 102:2183, 1934.Crossref
11.
Peters, V. M.:  Study of Survival in Hodgkin's Disease Treated Radiologically ,  Amer J Roentgenol 63:299, 1950.
12.
Peters Study of Survival in Hodgkin's Disease Treated Radiologically  Amer J Roentgenol 632991950: A Study of Hodgkin's Disease Treated by Irradiation.
13.
Dameshek, W.; Weisfuse, L.; and Stein, T.:  Nitrogen Mustard in Hodgkin's Disease, Analysis of Fifty Consecutive Cases ,  Blood 4:338, 1949.
14.
Goodman, L., and Gilman, A.:  Pharmacological Basis of Therapeutics , ed. 2, New York: The Macmillan Company, 1956, p. 321.
15.
Christy, N. P.; Donn, A.; and Jacler, J. W.:  Inhibition by Aminopyrine of Adrenocortical Activation Caused by Pyrogenic Reaction ,  Pros Soc Exp Biol Med 91:453, 1956.Crossref
×